Safety and efficacy of ablative fractional CO2 laser thrapy for external genital and the vagina in women with breast cancer

Safety and efficacy of ablative fractional CO2 laser thrapy for external genital and the vagina in women with breast cancer - AFLT study for MMK

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027742

Enrollment

Registered

2017-06-13

Start date

2017-06-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptom of vulvovaginal atrophy caused from low estrogen state

Interventions

Smarttxide2

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: breast cancer patients with vulvovaginal atrophy symptoms

Exclusion criteria

Exclusion criteria: 1) heart disease 2) severely lung disease 3) pelvic organ prolapse (more than 3) 4) pregnancy

Design outcomes

Primary

Measure	Time frame
Effect of AFLT on breast cancer patients at pre, 3 months, 6 months and one year by questionnaire	—

Secondary

Measure	Time frame
Effect of AFLT on breast cancer patients at pre, 3 months, 6 months and one year by objective evaluation and questionnaire.	—

Countries

Japan

Contacts

Public ContactNoriko Ninomiya

Women Clinic LUNA SHINSAIBASHI Urology

ninomiya5829@yahoo.co.jp0662517505

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026